Historically, the use of CRBN as an E3 ligase developed from immunomodulatory imide drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide that exhibit their anti-cancer and immunosuppressant activity by binding the CRBN subunit of the CRL4ACRBN E3 ligase complex. This evidence concerns the gene CRBN and cancer.